Expansion Opportunities For KarXT Possible With Two Particular Advancements
The NDA of KarXT highlighted above deals with targeting of patients with schizophrenia. Hopefully, Karuna ends up receiving FDA approval of this drug for the treatment of this patient population. However, it’s also finding a way to develop KarXT as an adjunctive therapy. That is, to combine the use of it with a background antipsychotic for patients with schizophrenia.